PDCD1 and neoplasm: Both CTLA-4 and PD-1 were originally identified as co-inhibitory receptors on T cells; therefore, checkpoint blockade immunotherapy has concentrated on recovering T cell-mediated anti-tumor capacity to regress tumors (2).